Lung Cancer Screening Market Scope And Analysis

Report Code : TIPRE00029996
Category : Medical Device

Status : Published
No. of Pages : 188

Buy Now

Lung Cancer Screening Market Scope and Analysis by 2030

Buy Now

Lung Cancer Screening Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 2.33 Billion
Market Size by 2030	US$ 4.36 Billion
Global CAGR (2022 - 2030)	8.2%
Historical Data	2020-2021
Forecast period	2023-2030
Segments Covered	By Cancer Type Non-Small Cell Lung Cancer By Technology Low-Dose Computed Tomography Chest X-Ray Liquid Biopsy By Age Group 50 & Older and Below 50 By End User Hospitals Diagnostic Centers
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Intelerad Medical Systems Incorporated Nuance Communications Inc GE HealthCare Technologies Inc Medtronic Plc Canon Medical Systems Corp Koninklijke Philips NV Siemens AG CVS Health bioAffinity Technologies Inc

Lung Cancer Screening Market - Recent Developments:

Inorganic and organic strategies such as mergers and acquisitions are highly adopted by companies in the lung cancer screening market. A few recent key market developments are listed below:

In June 2022, Royal Philips teamed up with Biodesix, Inc. to incorporate the results of Biodesix’s Nodify Lung blood-based lung nodule risk assessment testing into Philips Lung Cancer Orchestrator lung cancer patient management system.
In August 2022, Intelerad Medical Systems acquired PenRad Technologies, Inc., a software provider for enhancing breast imaging and lung screening productivity. The acquisition has expanded Intelerad’s product offerings for mammography and lung analytics, optimizing workflow for radiologists and boosting patient health outcomes.
In May 2021, Genetron Holdings Limited partnered with Siemens Healthineers at the China Medical Equipment Fair. This partnership promoted the large-scale application of Genetron’s S5 platform and lung cancer 8-gene IVD assay in Chinese hospitals and provided NSCLC patients with efficient and accurate personalized diagnosis and treatment guidance.